These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38. Bolzoni M; Toscani D; Costa F; Vicario E; Aversa F; Giuliani N Immunol Lett; 2019 Jan; 205():65-70. PubMed ID: 29702149 [TBL] [Abstract][Full Text] [Related]
30. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future. Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636 [TBL] [Abstract][Full Text] [Related]
31. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446 [TBL] [Abstract][Full Text] [Related]
33. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 Gogishvili T; Danhof S; Prommersberger S; Rydzek J; Schreder M; Brede C; Einsele H; Hudecek M Blood; 2017 Dec; 130(26):2838-2847. PubMed ID: 29089311 [TBL] [Abstract][Full Text] [Related]
34. The Anti-CD38 Antibody Therapy in Multiple Myeloma. Petrucci MT; Vozella F Cells; 2019 Dec; 8(12):. PubMed ID: 31842517 [TBL] [Abstract][Full Text] [Related]
35. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Horenstein AL; Bracci C; Morandi F; Malavasi F Front Immunol; 2019; 10():760. PubMed ID: 31068926 [TBL] [Abstract][Full Text] [Related]
36. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Abramson HN Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544512 [TBL] [Abstract][Full Text] [Related]
37. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Geis M; Nowotny B; Bohn MD; Kouhestani D; Einsele H; Bumm T; Stuhler G Commun Biol; 2021 Jan; 4(1):44. PubMed ID: 33420283 [TBL] [Abstract][Full Text] [Related]
38. Cell-based immunotherapy approaches for multiple myeloma. Kriegsmann K; Kriegsmann M; Cremer M; Schmitt M; Dreger P; Goldschmidt H; Müller-Tidow C; Hundemer M Br J Cancer; 2019 Jan; 120(1):38-44. PubMed ID: 30518815 [TBL] [Abstract][Full Text] [Related]
39. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. Braunstein M; Weltz J; Davies F Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179 [TBL] [Abstract][Full Text] [Related]
40. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma. Atanackovic D; Luetkens T; Radhakrishnan S; Kroger N Curr Cancer Drug Targets; 2017; 17(9):839-845. PubMed ID: 28875836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]